Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid, Clarient, Prediction Sciences

Cepheid announced this week that it is shipping new versions of its GeneXpert system.
The company said the new system offers increased color capability, detection of up to 60 targets in one cartridge, and software for integrating laboratory information systems.

Clarient announced this week plans to commercialize a breast cancer test applicable for all stages of operable breast cancer, including lymph node-positive patients.
According to Clarient, its test, called Insight Dx Breast Cancer Profile, is the first molecular test of its kind.
Clarient holds an exclusive licensing agreement with Prediction Sciences to sell the test.
The Insight Dx Breast Cancer Profile comprises “a series of molecular assays that, when combined using Prediction Sciences' proprietary algorithm, offer information designed to help individual patients and their physicians understand the risk of recurrence and assist them in selecting the most appropriate therapy,” Clarient said in a statement.
“The profile could allow patients to avoid the toxic effects of unnecessary chemotherapy, thereby reducing the overall cost of care,” the company stated.
The Insight Dx Breast Cancer Profile will enter a competitive breast cancer recurrence testing market valued at between $300 million and $400 million annually in the US. Currently several companies, including Genomic Health, Agendia, and Exagen, market breast cancer recurrence tests.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.